New pill plus chemo for untreated T-follicular helper cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new pill (golidocitinib) combined with standard chemotherapy for people with a specific type of lymphoma that hasn't been treated before. The goal is to see if adding the pill helps control the cancer better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of T-follicular helper (TFH) cell lymphoma, a type of lymphoma that affects certain immune cells.
- You have not yet received any systemic treatment for this lymphoma (chemotherapy, immunotherapy, or similar).
- You are between 18 and 74 years old.
- You are generally able to take care of yourself and are not bedridden (performance status 0-1).
- Your organ and bone marrow functions are adequate, as determined by blood tests.
- You do not have certain serious conditions, such as heart disease, active infections, other cancers (except skin basal cell), or a history of lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial is testing a new oral medication (golisitinib) in people with untreated intestinal T-cell lymphoma to see if it can help control the disease. The study focuses on safety and effectiveness, and is for those who have not had prior treatment for this condition.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a new targeted pill (golidocitinib) combined with two standard chemotherapy drugs (gemcitabine and oxaliplatin, known as GemOx) for people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and works better than current options.
Hear when a new Nodal T-follicular Helper Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.